Incidence of Microcarcinoma and Non-Microcarcinoma in Ultrasound-Found Thyroid Nodules

Zhi Chen
The Third Affiliated Hospital of Southern Medical University

Singla Sethiel Mosha
Guangzhou Medical University Second Affiliated Hospital

Tong Zhang
The Third Affiliated Hospital of Southern Medical University

Ming Xu
Guangzhou Medical University Second Affiliated Hospital

Yanli Li
Guangzhou Medical University Second Affiliated Hospital

Zhuoqing Hu
Guangzhou Medical University Second Affiliated Hospital

Weiqiang Liang
Southern Medical University Affiliated Nanhai Hospital

Xiaoyi Deng
Guangzhou Medical University Second Affiliated Hospital

Tingting Ou
Guangzhou Medical University Second Affiliated Hospital

Ling Li (✉ alana3344@sina.com)
Guangzhou Medical University Second Affiliated Hospital

Wangen Li
Guangzhou Medical University Second Affiliated Hospital

Research article

Keywords: Thyroid nodules, Ultrasound, Carcinomas, Screen

DOI: https://doi.org/10.21203/rs.3.rs-150354/v1

License: ☕️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Backgrounds: The incidence of thyroid nodules is increasing year by year around the world. However, ultrasound is not recommended as a screening test for the general population or patients with a normal thyroid on palpation by the American Association of Clinical Endocrinologists (AACE). In practice, some individuals with normal thyroid palpation have nodules that can just be found out by ultrasound. No studies have directly described the risk of nodules found by ultrasound or by palpation up to now. More evidence is needed to carry out for helping us balance the over diagnosis and missed diagnosis of malignant lesions. Therefore, we carried out a retrospective study to investigate the incidence of malignant lesions in ultrasound-found nodules in a large cohort.

Methods: We conducted a retrospective analysis involving 2957 patients who underwent thyroid ultrasound evaluation and fine-needle aspiration (FNA) between Jan 2013 and Dec 2019. The cytologic examinations were analyzed based on the Bethesda system. For nodules suspected to be follicular neoplasm or other malignant tumors by cytological tests, patients were recommended for surgery and histopathology examinations.

Results: Compared with palpation-found nodules, ultrasound-found nodules were presenting less as purely cystic nodules (10.1% vs 39.9%, \( \chi^2=355.69, p=0.000 \)), smaller size (17.5±9.9 mm vs 28.0±12.5 mm, \( t=23.876, p=0.000 \)), and higher TI-RADS score (5.5±2.9 vs 3.4±3.3, \( t=18.084, p=0.000 \)), respectively. More ultrasound-found nodules were diagnosed as carcinoma by histology examinations [136 (11.2%) nodules found by ultrasound vs 68 (3.9%) by palpation, \( \chi^2=59.737, p=0.000 \)], and 88 (64.7%) nodules found by ultrasound were non-microcarcinoma. Among the malignant nodules confirmed by histopathology, a higher proportion of microcarcinoma was detected in ultrasound-found nodules [35.3% (48/136) vs 16.2% (11/68), \( \chi^2=8.183, p=0.004 \)].

Conclusions: In view of the results observed in our research that malignant nodules were more common screened out by ultrasound, and nearly two thirds of them were non-microcarcinoma. We recommend reassessment of the recommendations for thyroid nodule screening.

Background

The incidence rate of thyroid nodules has an annual increasing trend worldwide. The overall prevalence rate was 49%-68% in general population of China, Europe and America by using ultrasound [1–3]. As thyroid nodules are usually the first sign of cancer, the primary goal of treatment is to distinguish between malignant and benign lesions.

In practice, more and more physicians took thyroid ultrasound as the preferred examination because of its noninvasive and inexpensive. However, recent researches reported that screening for thyroid cancer has led to a significant increase in the global diagnosis rate of the disease, but no change in mortality [4, 5]. Therefore, the American Association of Clinical Endocrinologists (AACE) does not recommend ultrasound as a screening test for the general population or patients with a normal thyroid on palpation.
and a low clinical risk of thyroid disease [6]. Similarly, The United States Preventive Services Task Force recommends against screening for thyroid cancer in asymptomatic adults [7]. Nevertheless, the AACE prescription standard for ultrasound screening is only at a level 4 evidence and GRADE C recommendation, which means it is based on expert experience with no conclusive risks or benefits [6]. It is necessary to investigate the characteristics of thyroid nodules only detected by ultrasound, therefore to determine whether it is necessary to conduct ultrasound examination for patients with no nodules found by palpation.

Up to now, no studies have directly compared the risk of ultrasound-found and palpation-found nodules. More researches evidence is needed to carry out for accumulating evidence to help us balance the over diagnosis and missed diagnosis of malignant lesions.

The purpose of this retrospective study was to investigate the incidence of malignant lesions in ultrasound-found nodules.

**Methods**

**Patients**

We conducted a retrospective analysis involving 2957 patients who underwent thyroid ultrasound evaluation and fine-needle aspiration (FNA) between January 2013 and December 2019. Patients were divided into two groups according to the detection way of the nodules. The ultrasound-found group refers to nodules discovered by ultrasound examination. The palpation-found group means that the nodules were found by patients themselves or by physicians when performing physical examination.

**Ultrasound Evaluation**

Risk of nodules was reported by ACR thyroid imaging, reporting and data system (TI-RADS) [8]. The characteristics of thyroid nodules were evaluated from five categories: composition, echogenicity, shape, margin, and echogenic foci. Each category has a score, and a total score was obtained by adding the five scores, which is the TI-RADS score. The size of nodules was expressed by the maximum diameter.

**Cytology And Histology Examinations**

FNA was performed by a conventional method, and at least two samples were taken per nodule. All our FNA samples were diagnosed at Guangzhou Kingmed Diagnostics which is the first pathology laboratory certified by the College of American Pathologists in China [9]. Cytology reports were based on the Bethesda system [10]. Six diagnostic categories include: (I) non-diagnostic or unsatisfactory, (II) benign, (III) atypia or follicular lesion of undetermined significance, (IV) follicular neoplasm, (V) suspicious for
malignancy and (VI) malignant. We recommended surgery for patients with the last three categories of cytological reports and obtained corresponding histologic reports.

**Statistical analysis**

All grouped data in accordance with normal distribution were described by mean ± standard deviation. The unpaired *t* test was used to compare the mean nodule size and TI-RADS score between ultrasound-found and palpation-found groups. The comparison of incidence for categorical data between groups was analyzed by chi-square test. Statistical analyses were performed using SPSS Statistics for Windows ver. 18.0. Statistical significance was defined if *p* < 0.05.

**Results**

**Characteristics Of Patients**

The characteristics of two groups of patients were shown in Table 1. Age, gender, course of disease, and body mass index (BMI) of patients were compared. There were no differences between two groups.

|                      | Ultrasound-found (n = 1212) | Palpation-found (n = 1745) |
|----------------------|----------------------------|---------------------------|
| Male (%)             | 296 (24.4)                 | 329 (18.9)                |
| Age (years)          | 48.3 ± 13.1                | 48.0 ± 14.5               |
| Course of disease (months)* | 2 (0.1, 240)           | 3 (0.1, 480)             |
| BMI (kg/m²)          | 23.1 ± 3.7                 | 22.5 ± 2.9               |

* Median (range)

**Characteristics Of Two Types Of Nodules**

In the group of ultrasound-found nodules, less purely cystic nodules were presented (10.1% vs 39.9%). The mean diameter of ultrasound-found nodules was 17.5 ± 9.9 whereas that of palpation-found nodules was 28.0 ± 12.5. A higher TI-RADS score was observed in the group of ultrasound-found nodules (28.0 ± 12.5), respectively. The details were shown in Table 2.
Table 2
Characteristics of two types of nodules

|                        | Ultrasound-found (n = 1212) | Palpation-found (n = 1745) | X² / t value | P value |
|------------------------|-----------------------------|----------------------------|--------------|---------|
| Purely cyst (n/%)      | 122 (10.1)                  | 697 (39.9)                 | 335.69       | 0.000   |
| Size (mm)              | 17.5 ± 9.9                  | 28.0 ± 12.5                | 23.876       | 0.000   |
| TI-RADS score          | 5.5 ± 2.9                   | 3.4 ± 3.3                  | 18.084       | 0.000   |

Incidence Of Thyroid Carcinoma On Histology

A higher proportion of malignant nodules were confirmed by histopathology in ultrasound group. As shown in Fig. 1, a total of 136 (11.2%) of ultrasound-found nodules and 68 (3.9%) of palpation-found nodules were diagnosed as carcinoma (x² = 59.737, p = 0.000).

Proportion Of Microcarcinoma And Non-microcarcinoma

Among carcinomas in ultrasound group, 35.3% (48/136) nodules were microcarcinomas (with a diameter smaller than 1 cm) and 64.7% (88/136) were non-microcarcinomas. More microcarcinoma was detected in malignant nodules found by ultrasound. 35.3% (48/136) ultrasound-found carcinomas and 16.2% (11/68) palpation-found ones were micro-carcinomas (x² = 8.183, p = 0.004), respectively (Fig. 2).

Discussion

Our study indicated that ultrasound-found nodules presented a greater malignancy risk than palpation-found ones. There were several explanations for the results. First, only 10% of ultrasound-found nodules were purely cystic, which are highly likely to be benign [6, 11]. In contrast to palpation-found ones, purely cystic nodules were nearly 40%. Second, though ultrasound-found nodules were smaller in size, they had higher TI-RADS score than palpation-found ones. Unlike palpation-found nodules, ultrasound-found nodules were smaller and often located deep in the thyroid tissue. Hence the relation of the nodule size between malignancy risk and prognosis as recommended by AACE became controversial [2].

Though some studies found that malignant risk is associated with nodule size, for example, a series of observational studies have found that thyroid cancers over 4 cm were associated with more aggressive behavior whereas tumors smaller than 1.5 cm had a good overall prognosis [12, 13, 14]. However, some other researches indicated no correlation between size and risk [15, 16]. A recent study found that the impact of nodule size on the malignancy risk differed according to the ultrasound pattern. A large nodule size (≥ 3 cm) showed a higher malignancy risk than smaller nodules in intermediate- and low-suspicion nodules [17].
We are convinced that our study findings as demonstrated above, highlight a conflict between AACE recommendations and clinical practice in the following aspects: AACE’s recommendation against ultrasound screening for thyroid nodules and the recommendation of FNA based on nodule size [6]. American Thyroid Association (ATA) also recommends FNA based on nodule size [11]. In our study, the average diameter of ultrasound-found nodules is 1.75 cm, which was within both of the recommended range of FNA.

Another conflict between AACE recommendations and recent reality highlighted in this study is that AACE recommends against ultrasound screening based on a significant increase in global thyroid cancer prevalence but a constant mortality rate [5, 6]. However, latest published study found that in America, incidence-based thyroid cancer mortality rose from 0.40 per 100,000 person-years in 1994–1997 to 0.46 per 100,000 person-years in 2010–2013 [18]. In China, the mortality increased from 0.30 per 100,000 in 2005 to 0.35 per 100,000 in 2015 [19].

Under current guidelines, only a small portion of patients could be under active surveillance for microcarcinoma [20]. Furthermore, in our study of ultrasound-found nodules, there were as high as two thirds that were non-microcarcinoma. For such large nodules, it is generally believed that the benefits of surgery outweigh the risks [6].

The limitation of this study is that ultrasound evaluations were performed by different operators and machines, so bias may exist.

In summary, since malignant nodules were more common in the ultrasound-found nodules, and nearly two thirds of which were non-microcarcinoma, we suggest the recommendation against screening thyroid nodules by ultrasound needs to be re-evaluated.

Abbreviations

AACE: American Association of Clinical Endocrinologists; ACR: American College of Radiology; ATA: American Thyroid Association; FNA: fine-needle aspiration; TI-RADS: Thyroid imaging reporting and data system

Declarations

Acknowledgements

None.

Authors’ contributions

L.L. and W.L. constructed the study design, interpreted the data, and drafted the report. Z.C. participated in data analysis and manuscript writing. All the other coauthors contributed to the discussion of the study protocol, data collection, and manuscript revision. All authors read and approved the final manuscript.
Funding

The present work was supported by grants from the Foundation of Guangdong Medical Science and Technology Research (No. A2019036).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was submitted to and approved by the Clinical Research Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University. Every participant signed a voluntary and written informed consent, and all the consents were obtained from the ethics committee.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Authors’ information

1Department of Endocrinology, The Second Affiliated Hospital, Guangzhou Medical University, No.250 Changgang Road East, Haizhu District, Guangzhou 510260, China. 2Department of Endocrinology, The Third Affiliated Hospital, Southern Medical University, No.183 Zhongshan Avenue West, Tianhe District, Guangzhou 510630, China. 3Department of Endocrinology, Affiliated Nanhai Hospital of Southern Medical University, No.40 Foping Road, Nanhai District, Foshan 528200, China. 4Department of Medical Ultrasound, The Second Affiliated Hospital, Guangzhou Medical University, No.250 Changgang Road East, Haizhu District, Guangzhou 510260, China;

References

1. Jiang H, Tian Y, Yan W, et al. The Prevalence of Thyroid Nodules and an Analysis of Related Lifestyle Factors in Beijing Communities. Int J Environ Res Public Health. 2016 Apr 22;13(4):442.

2. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) US examination. Eur J Clin Invest. 2009;39:699–706.

3. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–22.
4. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375:614–7.

5. Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26:1535–40.

6. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules—2016 update. Endocr Pract. 2016;22(5):622–39.

7. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. US Preventive Services Task Force. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317:1882–7.

8. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–95.

9. Zheng B, Zarka MA, Chen C, You J, Sun L, Chen L. The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data. J Am Soc Cytopathol. 2018;7(1):16–21.

10. Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159–65.

11. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.

12. Cavallo A, Johnson DN, White MG, et al. Thyroid nodule size at ultrasound as a predictor of malignancy and finalpathologic size. Thyroid. 2017;27(5):641–50.

13. Tam S, Amit M, Boonsripitayanon M, et al. Effect of tumor size and minimal extrathyroidal extension in patients with differentiated thyroid cancer. Thyroid. 2018;28:982–90.

14. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol. 2018;44:307–15. doi:10.1016/j.ejso.2017.03.004.

15. McHenry CR, Huh ES, Machekano RN. Is nodule size an independent predictor of thyroid malignancy? Surgery. 2008;144(6):1062–8.

16. Jinih M, Faisal F, Abdalla K, et al. Association between thyroid nodule size and malignancy rate. Ann R Coll Surg Engl. 2020;102(1):43–8.

17. Hong MJ, Na DG, Baek JH, Sung JY, Kim JH. Impact of Nodule Size on Malignancy Risk Differs according to the Ultrasonography Pattern of Thyroid Nodules. Korean J Radiol. 2018;19(3):534–41.

18. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–48.
19. Wang J, Yu F, Shang Y, Ping Z, Liu L. Thyroid cancer: incidence and mortality trends in China, 2005–2015. Endocrine. 2020 Jan 30.

20. Ito Y, Miyauchi A, Kudo T, et al. Trends in the implementation of active surveillance for low-risk papillary thyroid microcarcinomas at Kuma Hospital: gradual increase and heterogeneity in the acceptance of this new management option. Thyroid. 2018;28(4):488–95.

**Figures**

![Figure 1](attachment:image.png)

**Figure 1**

Comparison of the incidence of thyroid carcinoma between ultrasound group and palpation group
Figure 2

Comparison of the proportion of microcarcinoma between ultrasound group and palpation group